Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma
Cited by 46
Related Papers
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin’s Lymphoma
|Molecular Therapy — Oncolytics|2019|166
The Bruton's tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages
|Oncotarget|2017|86
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study
|The Lancet Oncology|2023|55
ITK inhibition induced in vitro and in vivo anti-tumor activity through downregulating TCR signaling pathway in malignant T cell lymphoma
|Cancer Cell International|2019|38
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma
|Journal of Experimental & Clinical Cancer Research|2019|34